Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.
OBJECTIVE
The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors.


METHODS
Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma.


RESULTS
There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC.


CONCLUSIONS
Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.
Worley
Michael J
MJ
Department of Obstetrics and Gynecology, New York Presbyterian Hospital-Cornell University Medical Center, New York, NY, USA. mworleyjr@gmail.com
Landen
Charles N
CN
Slomovitz
Brian M
BM
Malpica
Anais
A
Palla
Shana L
SL
Ramirez
Pedro T
PT
D000117:Acetylglucosamine / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D002277:Carcinoma / Q000145:classification* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D003537:Cystadenoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D004727:Endothelium / Q000503:physiopathology; D005260:Female; D020869:Gene Expression Profiling; D018014:Gene Transfer Techniques; D005909:Glioblastoma / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D006031:Glycosylation; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D037102:Lectins / Q000737:chemistry; D008297:Male; D008562:Membrane Glycoproteins / Q000737:chemistry* / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D017351:N-Acetylglucosaminyltransferases / Q000378:metabolism*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D010053:Ovary / Q000503:physiopathology; D016612:Paraffin Embedding; D010835:Phytohemagglutinins / Q000737:chemistry*; D011237:Predictive Value of Tests; D050717:Retinoblastoma-Like Protein p130 / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D014183:Transplantation, Heterologous
D014408:Biomarkers, Tumor; D037102:Lectins; D008562:Membrane Glycoproteins; D010835:Phytohemagglutinins; D050717:Retinoblastoma-Like Protein p130; C067494:erythroagglutinating phytohemagglutinin; D017351:N-Acetylglucosaminyltransferases; D000117:Acetylglucosamine